EUVIMEDEUVIMED entdecken
Open Access · CC0

Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical Trial

Hamdee Attallah, Anne L Friedlander, Matilde Nino-Murcia, Andrew R Hoffman

PLoS Clinical Trials · 04.05.2007 · 2 (5) · e21

DOI: 10.1371/journal.pctr.0020021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLoS Clinical Trials, online erschienen am 04.05.2007. Verfasst von Hamdee Attallah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Wayne State University, Detroit, Michigan, United States of America. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally obese adults with impaired glucose tolerance were evaluated under the hypothesis that the combination attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue (VAT), and improves insulin sensitivity over time. DESIGN: Randomized, double-blind, placebo-controlled, 2 x 2 factorial design. SETTING: Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States. PARTICIPANTS: 62 abdominally obese adults aged 40-75 with impaired glucose tolerance. INTERVENTIONS: GH (8 microg/kg/d, or placebo) and pioglitazone (30 mg/d, or placebo) for 40 wk. OUTCOME MEASURES: Baseline and after 40 wk of treatment, VAT content was quantified by CT scan, glucose tolerance was assessed using a 75-g oral glucose tolerance test, and insulin sensitivity was measured using steady-state plasma glucose levels obtained during insulin suppression test. RESULTS: BASELINE: body mass index (BMI), plasma glucose, and visceral fat content were similar. 40 wk: visceral fat area declined 23.9 +/- 7.4 cm(2) in GH group, mean difference from placebo: -28.1 cm(2) (95% CI -49.9 to -6.3 cm(2); p = 0.02). Insulin resistance declined 52 +/- 11.8 mg/dl with PIO, mean difference from placebo of -58.8 mg/dl (95% CI -99.7 to -18.0 mg/dl; p = 0.01). VAT and SSPG declined with GH and PIO combined, mean differences from placebo of -31.4 cm(2) (95% CI -56.5 cm(2) to -6.3 cm(2); p = 0.02) and -55.3 mg/dl (95% CI -103.9 to -6.7 mg/dl; p = 0.02), respectively. Fasting plasma glucose increased transiently in GH group. No significant changes in BMI were observed. CONCLUSIONS: Addition of PIO to GH attenuated the short-term diabetogenic effect of GH; the drug combination reduced VAT and insulin resistance over time. GH plus PIO may have added benefit on body composition and insulin sensitivity in the metabolic syndrome.

Autor:innen und Institutionen

  • Department of Medicine, Wayne State University, Detroit, Michigan, United States of America.

Zitieren

APA

Attallah, H., Friedlander, A. L., Nino-Murcia, M., & Hoffman, A. R. (2007). Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical Trial. PLoS Clinical Trials, 2(5), e21. https://doi.org/10.1371/journal.pctr.0020021

Vancouver

Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR. Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical Trial. PLoS Clinical Trials. 2007;2(5):e21. doi:10.1371/journal.pctr.0020021

BibTeX
@article{Attallah2007,
  author = {Attallah, Hamdee and Friedlander, Anne L and Nino-Murcia, Matilde and Hoffman, Andrew R},
  title = {Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical Trial},
  journal = {PLoS Clinical Trials},
  year = {2007},
  volume = {2},
  number = {5},
  pages = {e21},
  doi = {10.1371/journal.pctr.0020021}
}
Kostenlos starten →